Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo.
about
Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38.A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promotersDissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effectsDiscovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activitySelective glucocorticoid receptor-activating adjuvant therapy in cancer treatmentsGlucocorticoids inhibit lipopolysaccharide-induced up-regulation of arginase in rat alveolar macrophagesEvaluation of the selective glucocorticoid receptor agonist compound A for ototoxic effectsStructural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.Glucocorticoids antagonize AP-1 by inhibiting the Activation/phosphorylation of JNK without affecting its subcellular distribution.Transcriptional potencies of inhaled glucocorticoids.Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatasesMinireview: latest perspectives on antiinflammatory actions of glucocorticoids.Ginsenoside Rh1 potentiates dexamethasone's anti-inflammatory effects for chronic inflammatory disease by reversing dexamethasone-induced resistance.Molecular genetic analysis of glucocorticoid signaling using the Cre/loxP system.Molecular mechanisms of glucocorticoid action: what is important?New perspectives in asthma treatment.New approaches to topical therapy.A fully dissociated compound of plant origin for inflammatory gene repressionNoncanonical mechanisms to regulate nuclear receptor signaling.Molecular mechanisms of corticosteroids in allergic diseases.Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor.Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids.Advances in glucocorticoid-induced osteoporosisThe glucocorticoid RU24858 does not distinguish between transrepression and transactivation in primary human eosinophils.Glucocorticoid resistance in childhood leukaemia: mechanisms and modulation.Nontranscriptional actions of the glucocorticoid receptor.Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's diseaseHow corticosteroids control inflammation: Quintiles Prize Lecture 2005Involvement of simultaneous multiple transcription factor expression, including cAMP responsive element binding protein and OCT-1, for synovial cell outgrowth in patients with rheumatoid arthritisGlucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cellClinical trials for cytoprotection in stroke.The possible separation of 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation and hyperplasia by compound A.Dexamethasone and RU24858 Induce Survival and Growth Factor Receptor Bound Protein 2, Leukotriene B4 Receptor 1 and Annexin-1 Expression in Primary Human Neutrophils.Glucocorticoids for human skin: new aspects of the mechanism of action.Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems.Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index.GR SUMOylation and formation of an SUMO-SMRT/NCoR1-HDAC3 repressing complex is mandatory for GC-induced IR nGRE-mediated transrepressionDexamethasone-mediated changes in adipose triacylglycerol metabolism are exaggerated, not diminished, in the absence of a functional GR dimerization domain.
P2860
Q24537701-827964ED-960F-428C-A51D-334127704060Q24559978-4163A2D6-B608-4296-B508-7F87B1457AD3Q24630458-9D0E6A81-4963-47CB-A117-E5CCAEA4C280Q26782111-69FBEE6B-46D3-4AB2-A8F5-32645F09C7B4Q28078896-56CDE22F-A347-47E8-B0B0-0D8D2193394AQ28566905-2D082846-D1E2-4542-9F93-AC4E00C48BD2Q30382813-E5EE37FD-38CF-43FE-B355-25BB8D5E80B2Q30418832-4444C9AE-5970-48CF-8054-002D01B6D3FFQ30918621-709DE212-FC81-4B93-B707-2E695DC8122FQ31409970-B0A1165A-BA8F-4966-9643-F60B2E94B971Q33636430-38403D4F-8C59-4C7F-B9CA-FAA33F9EF717Q33670499-5A4DB1F4-1BD9-41E7-8F32-D015982F0FDEQ33767092-ACD915AF-DDDD-4417-86A9-2BC00DF0FA46Q33925125-8A39C063-EA98-4F11-8AD9-E59B16AABF90Q33944529-B85468D8-7328-4A20-8340-C12AA26FD8C4Q33987222-3AF2E02D-CA5A-4B40-8B38-08C2182D82ABQ34106948-EF9654B6-B893-45DB-A81A-878DF6BB5EF0Q34115914-422D5A97-B76E-4411-9C94-3B02E660491FQ34338685-8A72EE6A-FF1E-4945-90D0-26F8261AA6A5Q34383896-849D152F-CA6F-4A40-AB65-49F1381A4AD8Q34548430-F42BC1C7-EF52-4240-9EEB-E455AD05DC9CQ34563775-FAB57EA8-EFF9-4496-B9CC-10A009108517Q34717142-44F8E39F-0A9A-495A-899A-B7FD45A1D5FFQ34816365-016B6CDD-265B-448B-8030-907BADC7FC60Q34975913-5B0668DA-380A-417C-949D-ACA792F9624BQ35016058-1A4AF183-C4E9-4D96-ADA4-73FFFA8B96B5Q35089181-A971BFAA-D1D2-4664-872B-58B3C2475EE1Q35102215-4913CF72-E610-4F49-8554-12BDD3908A68Q35357667-B8111C7C-5B9D-468F-A1B9-FB939CC5F1FDQ35545886-F2922D28-4580-4DCA-801A-45D135B3D3A3Q35548076-F44466F1-8ECF-481E-954A-51FA447FC83EQ35666145-CE82783F-25C4-42D3-96CE-6469646C4044Q36045223-A463430C-E415-4139-BF7A-DD4D742010CEQ36078315-9C34D4F5-1B99-48BA-A7D7-09C87CBF553CQ36093245-723251A4-B801-45BB-BDCE-63514C9D0F04Q36129596-6B1CE2BA-1825-41AA-B957-5A9EAE69E9A7Q36316793-D53B5870-F2FD-478E-AC60-5541CBA38B1CQ36536770-1E3CAFF2-BA9D-4F63-85AB-BECB019B6D78Q36563336-9FE6C399-C10D-43B2-ABE7-7232947F9121Q36699512-481CA53E-34AB-491E-A1C6-D9BB1F75993B
P2860
Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo.
description
1997 nî lūn-bûn
@nan
1997 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Synthetic glucocorticoids that ...... inflammatory activity in vivo.
@ast
Synthetic glucocorticoids that ...... inflammatory activity in vivo.
@en
Synthetic glucocorticoids that ...... inflammatory activity in vivo.
@nl
type
label
Synthetic glucocorticoids that ...... inflammatory activity in vivo.
@ast
Synthetic glucocorticoids that ...... inflammatory activity in vivo.
@en
Synthetic glucocorticoids that ...... inflammatory activity in vivo.
@nl
prefLabel
Synthetic glucocorticoids that ...... inflammatory activity in vivo.
@ast
Synthetic glucocorticoids that ...... inflammatory activity in vivo.
@en
Synthetic glucocorticoids that ...... inflammatory activity in vivo.
@nl
P2093
P356
P1476
Synthetic glucocorticoids that ...... inflammatory activity in vivo.
@en
P2093
Choquart A
Gronemeyer H
Marchandeau C
Resche-Rigon M
Vayssière BM
P304
P356
10.1210/ME.11.9.1245
P577
1997-08-01T00:00:00Z